Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the acquisition, development, and commercialization of branded prescription products. The company's mission is to deliver unique products that enhance the quality of patient care.

Cumberland Pharmaceuticals serves market segments including hospital acute care, gastroenterology, and oncology. Its portfolio of FDA-approved brands includes Acetadote (acetylcysteine) for acetaminophen poisoning, Caldolor (ibuprofen) for pain and fever, Kristalose (lactulose) for constipation, Sancuso (granisetron) for chemotherapy-induced nausea and vomiting, Vaprisol (conivaptan) for hyponatremia, Vibativ (telavancin) for serious bacterial infections, and Talicia (omeprazole, amoxicillin, and rifabutin) for H. pylori infection. The company also has a pipeline of product candidates, including ifetroban (Dyscorban, Vasculan, Fibroban) in Phase 2 clinical programs for conditions such as Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis.

Led by CEO A.J. Kazimi, Cumberland Pharmaceuticals has recently announced significant developments. In April 2026, the company entered an agreement with Apotex for the integration of its branded U.S. businesses, involving the acquisition of Cumberland's branded pharmaceuticals for $100 million. Earlier, in February 2025, breakthrough results were reported from the Phase 2 FIGHT DMD trial for Duchenne Muscular Dystrophy heart disease, utilizing its investigational product ifetroban, which has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA. The company also expanded its global reach in 2025 with Vibativ approvals and launches in China and Saudi Arabia, and ibuprofen injection approval in Mexico. For the full year 2025, Cumberland Pharmaceuticals reported $44.5 million in revenues, marking an 18% increase over the prior year.